MarketBeat cites USD 52.38 target for UroGen Pharma stock

Published on 10/15/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UroGen Pharma posted USD 72.5 million in second-quarter 2026 revenue. UroGen Pharma stock costs EUR 32.71 on October 15, 2026 at Lang & Schwarz.

Analyst target and earnings date

MarketBeat reported a USD 52.38 average target on October 12, 2026.
Second-quarter 2026 revenue reached USD 72.5 million, versus USD 24.2 million a year earlier.
UroGen Pharma stock traded at EUR 32.71 at 1:40 p.m. CEST at Lang & Schwarz on October 15, 2026.
UroGen Pharma is estimated to report third-quarter results on November 5, 2026.

URGN, IL0011407140, Illustration mit AI erstellt.

UroGen Pharma (IL0011407140) has a USD 52.38 average 12-month price target, according to MarketBeat on October 12, 2026. The target follows a second-quarter revenue jump and gives investors a clear benchmark ahead of the next report.

Revenue growth drives the case

UroGen generated USD 72.5 million in revenue in the second quarter of 2026, compared with USD 24.2 million in the second quarter of 2025. The figure came alongside a net loss of USD 14.4 million, or USD 0.28 per diluted share, according to the company's second-quarter earnings call transcript dated August 5, 2026, published by Yahoo Finance.

The commercial engine is increasingly concentrated in ZUSDURI. Management said the product generated USD 50.4 million in second-quarter 2026 net product revenue, up 73.00 percent from the first quarter, while JELMYTO revenue reached USD 22.0 million. The company maintained 2026 JELMYTO revenue guidance of USD 97 million to USD 101 million.

What does the target imply?

MarketBeat reported eight buy ratings, one hold rating and one sell rating, producing the USD 52.38 average target across ten brokerages on October 12, 2026. The same report said the latest quarterly revenue exceeded the USD 63.55 million consensus estimate, while the USD 0.28 loss per share was wider than the USD 0.26 expected loss.

Three dates frame the story

On August 5, 2026, UroGen reported USD 72.5 million in second-quarter revenue through its earnings call. On August 17, 2026, the company listed its NDA submission for UGN-103 in its investor-relations news releases. On October 8, 2026, CFO Chris Degnan sold 2,202 shares at an average price of USD 36.69, a transaction reported by MarketBeat.

Next reporting date

MarketBeat estimates that UroGen will report third-quarter 2026 results on November 5, 2026, before the market opens, with a conference call scheduled for 10:00 a.m. ET.

Stock price and valuation context

UroGen's Nasdaq listing had a market capitalization of USD 1.8 billion as of October 14, 2026. Its 52-week range was USD 16.36 to USD 50.81, leaving the valuation highly sensitive to execution in ZUSDURI and the timing of pipeline milestones. The company describes itself as a biopharmaceutical developer focused on cancers of the urinary tract.

UroGen Pharma was trading at EUR 32.71 at Lang & Schwarz on October 15, 2026 at 1:40 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of UroGen Pharma stock.